These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 18171383

  • 1. Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta.
    Gibbs E, Tremlett H, Ball N, Hashimoto S.
    Eur J Neurol; 2008 Jan; 15(1):e4. PubMed ID: 18171383
    [No Abstract] [Full Text] [Related]

  • 2. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
    Hoffmann LA, Krumbholz M, Faber H, Kuempfel T, Starck M, Pöllmann W, Meinl E, Hohlfeld R.
    Neurology; 2007 Mar 20; 68(12):958-9. PubMed ID: 17372138
    [No Abstract] [Full Text] [Related]

  • 3. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H, Stelmasiak Z.
    Neurol Neurochir Pol; 2004 Mar 20; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [Abstract] [Full Text] [Related]

  • 4. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R, Stürzebecher CS, Kapp JF.
    Funct Neurol; 2001 Mar 20; 16(2):117-28. PubMed ID: 11495417
    [No Abstract] [Full Text] [Related]

  • 5. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.
    Giovannoni G.
    Neurology; 2003 Nov 11; 61(9 Suppl 5):S13-7. PubMed ID: 14610104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Pachner AR.
    Neurology; 2007 Oct 09; 69(15):1555; author reply 1565. PubMed ID: 17923620
    [No Abstract] [Full Text] [Related]

  • 8. Neutralising antibodies against interferon beta in multiple sclerosis.
    Giovannoni G, Deisenhammer F.
    Lancet; 2004 Jan 10; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177
    [No Abstract] [Full Text] [Related]

  • 9. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Sorensen PS, Bertolotto A.
    Neurology; 2007 Oct 09; 69(15):1552; author reply 1553. PubMed ID: 17923618
    [No Abstract] [Full Text] [Related]

  • 10. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta.
    Mayorga C, Luque G, Romero F, Guerrero R, Blanca M, Fernandez O.
    Int Arch Allergy Immunol; 1999 Oct 09; 118(2-4):368-71. PubMed ID: 10224450
    [No Abstract] [Full Text] [Related]

  • 11. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference.
    Hartung HP, Munschauer F, Schellekens H.
    Eur J Neurol; 2005 Aug 09; 12(8):588-601. PubMed ID: 16053466
    [Abstract] [Full Text] [Related]

  • 12. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab.
    Sørensen PS, Koch-Henriksen N, Jensen PE.
    Neurology; 2011 Feb 22; 76(8):759-60. PubMed ID: 21339504
    [No Abstract] [Full Text] [Related]

  • 13. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a.
    Schwid SR, Decker MD, Lopez-Bresnahan M, Rebif-Influenza Vaccine Study Investigators.
    Neurology; 2005 Dec 27; 65(12):1964-6. PubMed ID: 16380621
    [Abstract] [Full Text] [Related]

  • 14. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT.
    Arch Neurol; 2010 Apr 27; 67(4):386-7. PubMed ID: 20385901
    [No Abstract] [Full Text] [Related]

  • 15. Can we get rid of neutralizing antibodies against interferon-β?
    Buttmann M, Toyka KV.
    Eur J Neurol; 2009 Jan 27; 16(1):7-9. PubMed ID: 19087143
    [No Abstract] [Full Text] [Related]

  • 16. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS, European NABINMS Consortium.
    J Int Med Res; 2008 Jan 27; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
    [No Abstract] [Full Text] [Related]

  • 17. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J, Lublin FD.
    Adv Neurol; 2006 Jan 27; 98():257-71. PubMed ID: 16400838
    [No Abstract] [Full Text] [Related]

  • 18. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Ravnborg M, Bendtzen K, Christensen O, Jensen PE, Hesse D, Tovey MG, Sørensen PS.
    Mult Scler; 2009 Mar 27; 15(3):323-8. PubMed ID: 19028832
    [Abstract] [Full Text] [Related]

  • 19. Neutralising antibodies against interferon beta in multiple sclerosis.
    Mikol D.
    Lancet; 2004 Jan 10; 363(9403):167-8; author reply 168-9. PubMed ID: 14726179
    [No Abstract] [Full Text] [Related]

  • 20. Interferon-beta1b in multiple sclerosis.
    Buttmann M, Rieckmann P.
    Expert Rev Neurother; 2007 Mar 10; 7(3):227-39. PubMed ID: 17341170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.